Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

brequinar sodium

Known as: Sodium 6-Fluoro-2-(2'-fluoro-4-biphenylyl)-3-methyl-4-quinolinecarboxylate 
The sodium salt form of Brequinar. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This… Expand
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

DuP 785
NCIt Antineoplastic Agent Terminologybrequinar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2000
Highly Cited
2000
Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis… Expand
Highly Cited
1996
Highly Cited
1996
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
The active metabolite of leflunomide. A771726, is a novel immunosuppressive compound that has been shown to be a powerful… Expand
1994
1994
EVALUATION OF CYCLOSPORINE, MYCOPHENOLATE MOFETIL, AND BREQUINAR SODIUM COMBINATION THERAPY ON HAMSTER‐TO-RAT CARDIAC XENOTRANSPLANTATION
We examined the effect of CsA, mycophenolate mofetil (MM), and Brequinar sodium (BQR) combination therapy on hamster-to-rat… Expand
Review
1993
Review
1993
The Development of Brequinar as an Immunosuppressive Drug for Transplantation
The preclinical and clinical characterization of Brequinar sodium has demonstrated the potential for the use of this drug as a… Expand
1993
1993
The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination.
The rigorous median-effect analysis was used to assess the interactions between cyclosporine and drugs that inhibit nucleotide… Expand
Highly Cited
1992
Highly Cited
1992
Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
The novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390, 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Highly Cited
1992
Highly Cited
1992
THE EFFECT OF A NEW IMMUNOSUPPRESSIVE DRUG, BREQUINAR SODIUM, ON HEART, LIVER, AND KIDNEY ALLOGRAFT REJECTION IN THE RAT
Brequinar sodium (BQR) prevents cell proliferation by virtue of its inhibition of de novo pyrimidine biosynthesis. BQR is capable… Expand
1992
1992
Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
To verify the assumption of a specific and potent drug action on de novo pyrimidine biosynthesis, isolated dihydroorotate… Expand
Highly Cited
1990
Highly Cited
1990
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Little is known about the in vivo effects of inhibition of the mitochondrial pyrimidine de novo synthesis enzyme dihydroorotic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
1989
Highly Cited
1989
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Brequinar sodium is a 4-quinolinecarboxylic acid analogue that inhibits dihydroorotate dehydrogenase and subsequent de novo… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE